RECURRENT OVARIAN CANCER
Clinical trials for RECURRENT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to stall ovarian Cancer's return
Disease control OngoingThis study tests whether adding oregovomab to the standard drug niraparib can help control platinum-sensitive recurrent ovarian cancer. Ten adults whose cancer returned after initial chemotherapy will receive both drugs. The goal is to see if the combination shrinks tumors or kee…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated May 26, 2026 09:34 UTC
-
New drug cocktail targets Hard-to-Treat ovarian and uterine cancers
Disease control OngoingThis early-phase study tests a new investigational drug (RP-6306) combined with two standard chemotherapies (carboplatin and paclitaxel) in people with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find the safest dose…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 26, 2026 09:30 UTC